End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy.
Hannah E DzimitrowiczLauren E WilsonBradford E JacksonLisa P SpeesChristopher D BaggettMelissa A GreinerDeborah R KayeTian ZhangDaniel J GeorgeCharles D ScalesJessica E PritchardMichael S LeapmanCary P GrossMichaela A DinanStephanie B WheelerPublished in: JCO oncology practice (2022)
Patients with mRCC who received OAAs and younger patients experienced more aggressive EOL care, suggesting opportunities to optimize high-quality EOL care in these groups.